drugset
drugset / Trial / NCT03392116

Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult Subjects

NCT03392116 ↗

Phase 1 Completed 92 enrolled NGM Biopharmaceuticals, Inc
RandomizedFactorialDouble-blindTreatment

Summary

The purpose is to evaluate the safety, tolerability, and PK of NGM120 in healthy adult subjects

Timeline

Start
2018-01-29
Primary completion
2019-01-14
Completion
2019-03-11

Drugs

EvaluationDrugModalityDoseRoute
Subject NGM120 Monoclonal antibody — Subcutaneous

Indications

No indication recorded.